BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
0.00 (0.00%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.80 - 1.90
52 week 1.50 - 4.39
Open 1.85
Vol / Avg. 436,272.00/378,842.00
Mkt cap 101.47M
P/E     -
Div/yield     -
EPS -0.77
Shares 54.12M
Beta 1.02
Inst. own 49%
Mar 8, 2017
Q4 2016 BioDelivery Sciences International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 9, 2017
BioDelivery Sciences International Inc at JPMorgan Healthcare Conference
Dec 8, 2016
BioDelivery Sciences International Inc to Discuss the Transaction and BDSI's Initial Plans for BELBUCA Conference Call
Nov 30, 2016
BioDelivery Sciences International Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -447.41% -78.11%
Operating margin -425.62% -72.94%
EBITD margin - -70.25%
Return on average assets -89.35% -39.32%
Return on average equity -8258.19% -87.52%
Employees 40 -
CDP Score - -


4131 Parklake Avenue, Suite 225
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Officers and directors

Frank E. O'Donnell Jr. Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark A. Sirgo President, Chief Executive Officer, Vice Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 62
Bio & Compensation  - Reuters
Niraj Vasisht Senior Vice President, Chief Technology Officer
Bio & Compensation  - Reuters
Albert J. Medwar Senior Vice President - Corporate and Business Development
Bio & Compensation  - Reuters
Stephana E. Patton Ph.D. J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Sarah DeRossett Vice President - Clinical Research and Medical Affairs
Bio & Compensation  - Reuters
Joseph Lockhart Vice President - Manufacturing and Supply Chain
Bio & Compensation  - Reuters
Peter L. Ginsberg Vice President - Business Development
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 72
Bio & Compensation  - Reuters